Skip to content

Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn

Efficacy of Imipramine for Treatment of Patients With Esophageal

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01753128
Enrollment
83
Registered
2012-12-20
Start date
2012-12-31
Completion date
2013-09-30
Last updated
2014-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease

Brief summary

Esophageal hypersensitivity/Functional heartburn are common among non-erosive reflux disease (NERD) patients who do not response to proton pump inhibitors. Whether tricyclic antidepressant improves NERD patient's symptoms remains unknown Aim of this randomized controlled trial study is to determine the efficacy of imipramine, which could increase esophageal pain thresholds in healthy volunteers, in comparison with placebo for treatment patients with esophageal hypersensitivity or functional heartburn evaluated by improvement of specific-symptom score and quality of life

Interventions

DRUGimipramine

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient with typical reflux symptoms (heartburn and/or regurgitation) more than 3 times per week in at least last 3 months * Age more than 18 years * Upper GI endoscopy showed no esophageal mucosal breaks * MII-pH monitoring was not showed abnormal both acid and non-acid reflux * symptoms was not improved after received standard dose proton pump inhibitor for at least 1 month

Exclusion criteria

* history of thoracic, esophagus, or stomach surgery * severe esophageal motility disorder eg. Achalasia, scleroderma, autonomic/peripheral neuropathy/myopathy * patient who was indicated to receive proton pump inhibitor * pregnant women * patient who was allergy to imipramine * patient who received tricyclic antidepressant or SSRI with in 3 month of enrollment

Design outcomes

Primary

MeasureTime frame
improvement of GERD score6 months

Secondary

MeasureTime frame
improve quality of life6 months

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026